Eloxx Pharmaceuticals, Inc. (ELOX)
| Market Cap | 60.83M |
| Revenue (ttm) | n/a |
| Net Income | -10.65M |
| EPS | -2.84 |
| Shares Out | 4.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,078 |
| Open | 16.22 |
| Previous Close | 16.00 |
| Day's Range | 15.07 - 16.80 |
| 52-Week Range | n/a |
| Beta | -160,647.01 |
| Analysts | Strong Buy |
| Price Target | 40.33 (+167.62%) |
| Earnings Date | Aug 12, 2026 |
About ELOX
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations,... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ELOX stock is "Strong Buy." The 12-month stock price target is $40.33, which is an increase of 167.62% from the latest price.
News
Eloxx Pharmaceuticals initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and $38 price target The firm sees an attractive risk/reward ahead of the mid-2027 EXACT Phase 2b readout…
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial ...
Eloxx Pharmaceuticals Quarterly report: Q2 2026
Eloxx Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 11, 2026.
Eloxx Pharmaceuticals Earnings release: Q2 2026
Eloxx Pharmaceuticals released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Eloxx Pharmaceuticals initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Rami Katkhuda initiated coverage of Eloxx Pharmaceuticals (ELOX) with an Outperform rating and $40 price target
Eloxx Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim analyst Vamil Divan last night initiated coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and $43 price target The firm says its positive stance is driven by the…
Eloxx Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and $43 price target
Eloxx Pharmaceuticals Inc trading resumes
11:22 EDT Eloxx Pharmaceuticals (ELOX) Inc trading resumes
Eloxx Pharmaceuticals Inc trading halted, volatility trading pause
11:17 EDT Eloxx Pharmaceuticals (ELOX) Inc trading halted, volatility trading pause
Eloxx Pharmaceuticals Inc trading resumes
14:24 EDT Eloxx Pharmaceuticals (ELOX) Inc trading resumes
Eloxx Pharmaceuticals Inc trading halted, volatility trading pause
14:19 EDT Eloxx Pharmaceuticals (ELOX) Inc trading halted, volatility trading pause
Eloxx Pharmaceuticals Inc trading halted, volatility trading pause
09:30 EDT Eloxx Pharmaceuticals (ELOX) Inc trading halted, volatility trading pause
Eloxx Pharmaceuticals Inc trading resumes
09:40 EDT Eloxx Pharmaceuticals (ELOX) Inc trading resumes
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule produ...
Eloxx Pharmaceuticals Registration statement: Registration filing
Eloxx Pharmaceuticals filed a registration statement on June 4, 2026, providing details about a securities offering with the SEC.
Eloxx Pharmaceuticals Registration statement: Registration filing
Eloxx Pharmaceuticals filed a registration statement on June 1, 2026, providing details about a securities offering with the SEC.
Eloxx Pharmaceuticals Registration statement: Registration filing
Eloxx Pharmaceuticals filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Eloxx Pharmaceuticals Quarterly report: Q1 2026
Eloxx Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 5, 2026.
Eloxx Pharmaceuticals Annual report: Q4 2025
Eloxx Pharmaceuticals has published its Q4 2025 annual report on March 17, 2026.
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations
Eloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates
Eloxx Pharmaceuticals provided program updates for ELX-02 and ZKN-013, including Orphan Drug Designation for ELX-02. ELX-02: Regulatory and Clinical Updates for Alport Syndrome Nonsense Mutation Progr...
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome
Eloxx Pharmaceuticals treatment of Alport Syndrome granted FDA orphan status
Eloxx Pharmaceuticals’ treatment of Alport Syndrome was granted orphan status by the FDA, according to a post to the agency’s website.
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an e...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
BARCELONA, Spain & WATERTOWN, Mass.--(BUSINESS WIRE)--Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agr...